Startseite>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>>ETP 45658

ETP 45658

Katalog-Nr.GC50072

ETP 45658 ist ein potenter PI3K-Inhibitor mit IC50-Werten von 22,0 nM, 39,8 nM, 129,0 nM und 717,3 nM für PI3Kα, PI3Kδ, PI3Kβ bzw. PI3Kγ. ETP 45658 kann auch DNA-PK (IC50\u003d70,6 nM) und mTOR (IC50\u003d152,0 nM) hemmen. ETP 45658 kann für die Krebsforschung verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

ETP 45658 Chemische Struktur

Cas No.: 1198357-79-7

Größe Preis Lagerbestand Menge
10 mg
284,00 $
Auf Lager
50 mg
859,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PI 3-kinase inhibitor (IC50 values are 22, 30, 129 and 710 nM for PI 3-Kα, PI 3-Kδ, PI 3-Kβ and PI 3-Kγ respectively). Also inhibits DNA-PK and mTOR (IC50 values are 70.6 and 152 nM respectively). Inhibits proliferation of multiple cancer cell lines in vitro and reduces Akt phosphorylation levels in vivo.

Link et al (2009) Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J.Biol.Chem. 284 28392 PMID:19690175 |Hill et al (2014) A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 16 482 PMID:25488803

Bewertungen

Review for ETP 45658

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ETP 45658

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.